Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy

N. L. Henry, A. Nguyen, F. Azzouz, L. Li, J. Robarge, S. Philips, D. Cao, Todd Skaar, J. M. Rae, Anna Maria Storniolo, D. A. Flockhart, D. F. Hayes, V. Stearns

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Tamoxifen, a selective oestrogen receptor (ER) modulator, increases bone mineral density (BMD) in postmenopausal women and decreases BMD in premenopausal women. We hypothesised that inherited variants in candidate genes involved in oestrogen signalling and tamoxifen metabolism might be associated with tamoxifen effects in bone. Methods: A total of 297 women who were initiating tamoxifen therapy were enrolled in a prospective multicentre clinical trial. Lumbar spine and total hip BMD values were measured using dual-energy X-ray absorptiometry (DXA) at baseline and after 12 months of tamoxifen therapy. Single-nucleotide polymorphisms (SNPs) in ESR1, ESR2, and CYP2D6 were tested for associations in the context of menopausal status and previous chemotherapy, with a mean percentage change in BMD over 12 months. Results: The percentage increase in BMD was greater in postmenopausal women and in those patients who had been treated with chemotherapy. No significant associations between tested SNPs and either baseline BMD or change in BMD with 1 year of tamoxifen therapy were detected. Conclusion: The evaluated SNPs in ESR and CYP2D6 do not seem to influence BMD in tamoxifen-treated subjects.

Original languageEnglish
Pages (from-to)294-300
Number of pages7
JournalBritish Journal of Cancer
Volume102
Issue number2
DOIs
StatePublished - Jan 2010

Fingerprint

Tamoxifen
Estrogen Receptors
Bone Density
Single Nucleotide Polymorphism
Cytochrome P-450 CYP2D6
Therapeutics
Pelvic Bones
Selective Estrogen Receptor Modulators
Drug Therapy
Photon Absorptiometry
Multicenter Studies
Estrogens
Spine
Clinical Trials
Bone and Bones
Genes

Keywords

  • Bone mineral density
  • Chemotherapy
  • CYP2D6
  • Oestrogen receptor
  • Polymorphism
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. / Henry, N. L.; Nguyen, A.; Azzouz, F.; Li, L.; Robarge, J.; Philips, S.; Cao, D.; Skaar, Todd; Rae, J. M.; Storniolo, Anna Maria; Flockhart, D. A.; Hayes, D. F.; Stearns, V.

In: British Journal of Cancer, Vol. 102, No. 2, 01.2010, p. 294-300.

Research output: Contribution to journalArticle

Henry, NL, Nguyen, A, Azzouz, F, Li, L, Robarge, J, Philips, S, Cao, D, Skaar, T, Rae, JM, Storniolo, AM, Flockhart, DA, Hayes, DF & Stearns, V 2010, 'Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy', British Journal of Cancer, vol. 102, no. 2, pp. 294-300. https://doi.org/10.1038/sj.bjc.6605460
Henry, N. L. ; Nguyen, A. ; Azzouz, F. ; Li, L. ; Robarge, J. ; Philips, S. ; Cao, D. ; Skaar, Todd ; Rae, J. M. ; Storniolo, Anna Maria ; Flockhart, D. A. ; Hayes, D. F. ; Stearns, V. / Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. In: British Journal of Cancer. 2010 ; Vol. 102, No. 2. pp. 294-300.
@article{56c5d242e47f46f0b1236a3d1647a6e0,
title = "Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy",
abstract = "Background: Tamoxifen, a selective oestrogen receptor (ER) modulator, increases bone mineral density (BMD) in postmenopausal women and decreases BMD in premenopausal women. We hypothesised that inherited variants in candidate genes involved in oestrogen signalling and tamoxifen metabolism might be associated with tamoxifen effects in bone. Methods: A total of 297 women who were initiating tamoxifen therapy were enrolled in a prospective multicentre clinical trial. Lumbar spine and total hip BMD values were measured using dual-energy X-ray absorptiometry (DXA) at baseline and after 12 months of tamoxifen therapy. Single-nucleotide polymorphisms (SNPs) in ESR1, ESR2, and CYP2D6 were tested for associations in the context of menopausal status and previous chemotherapy, with a mean percentage change in BMD over 12 months. Results: The percentage increase in BMD was greater in postmenopausal women and in those patients who had been treated with chemotherapy. No significant associations between tested SNPs and either baseline BMD or change in BMD with 1 year of tamoxifen therapy were detected. Conclusion: The evaluated SNPs in ESR and CYP2D6 do not seem to influence BMD in tamoxifen-treated subjects.",
keywords = "Bone mineral density, Chemotherapy, CYP2D6, Oestrogen receptor, Polymorphism, Tamoxifen",
author = "Henry, {N. L.} and A. Nguyen and F. Azzouz and L. Li and J. Robarge and S. Philips and D. Cao and Todd Skaar and Rae, {J. M.} and Storniolo, {Anna Maria} and Flockhart, {D. A.} and Hayes, {D. F.} and V. Stearns",
year = "2010",
month = "1",
doi = "10.1038/sj.bjc.6605460",
language = "English",
volume = "102",
pages = "294--300",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy

AU - Henry, N. L.

AU - Nguyen, A.

AU - Azzouz, F.

AU - Li, L.

AU - Robarge, J.

AU - Philips, S.

AU - Cao, D.

AU - Skaar, Todd

AU - Rae, J. M.

AU - Storniolo, Anna Maria

AU - Flockhart, D. A.

AU - Hayes, D. F.

AU - Stearns, V.

PY - 2010/1

Y1 - 2010/1

N2 - Background: Tamoxifen, a selective oestrogen receptor (ER) modulator, increases bone mineral density (BMD) in postmenopausal women and decreases BMD in premenopausal women. We hypothesised that inherited variants in candidate genes involved in oestrogen signalling and tamoxifen metabolism might be associated with tamoxifen effects in bone. Methods: A total of 297 women who were initiating tamoxifen therapy were enrolled in a prospective multicentre clinical trial. Lumbar spine and total hip BMD values were measured using dual-energy X-ray absorptiometry (DXA) at baseline and after 12 months of tamoxifen therapy. Single-nucleotide polymorphisms (SNPs) in ESR1, ESR2, and CYP2D6 were tested for associations in the context of menopausal status and previous chemotherapy, with a mean percentage change in BMD over 12 months. Results: The percentage increase in BMD was greater in postmenopausal women and in those patients who had been treated with chemotherapy. No significant associations between tested SNPs and either baseline BMD or change in BMD with 1 year of tamoxifen therapy were detected. Conclusion: The evaluated SNPs in ESR and CYP2D6 do not seem to influence BMD in tamoxifen-treated subjects.

AB - Background: Tamoxifen, a selective oestrogen receptor (ER) modulator, increases bone mineral density (BMD) in postmenopausal women and decreases BMD in premenopausal women. We hypothesised that inherited variants in candidate genes involved in oestrogen signalling and tamoxifen metabolism might be associated with tamoxifen effects in bone. Methods: A total of 297 women who were initiating tamoxifen therapy were enrolled in a prospective multicentre clinical trial. Lumbar spine and total hip BMD values were measured using dual-energy X-ray absorptiometry (DXA) at baseline and after 12 months of tamoxifen therapy. Single-nucleotide polymorphisms (SNPs) in ESR1, ESR2, and CYP2D6 were tested for associations in the context of menopausal status and previous chemotherapy, with a mean percentage change in BMD over 12 months. Results: The percentage increase in BMD was greater in postmenopausal women and in those patients who had been treated with chemotherapy. No significant associations between tested SNPs and either baseline BMD or change in BMD with 1 year of tamoxifen therapy were detected. Conclusion: The evaluated SNPs in ESR and CYP2D6 do not seem to influence BMD in tamoxifen-treated subjects.

KW - Bone mineral density

KW - Chemotherapy

KW - CYP2D6

KW - Oestrogen receptor

KW - Polymorphism

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=75549090761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75549090761&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6605460

DO - 10.1038/sj.bjc.6605460

M3 - Article

VL - 102

SP - 294

EP - 300

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -